Calreticulin Antibody (6C6) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-50053PCP
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human, Mouse, Rat
Applications
Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # 6C6
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Calreticulin Antibody (6C6) [PerCP]
Immunogen
Calreticulin Antibody (6C6) was developed against a synthetic peptide VESGSLEDDWDFLPPKKI corresponding to amino acids 191-208 of human Calreticulin, including the LC3 interacting region or LIR. [UniProt# P27797]
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for Calreticulin Antibody (6C6) [PerCP]
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Calreticulin
Given its role in multiple biological processes, it makes sense that calreticulin is implicated in both healthy and disease states. Studies have found that calreticulin mutations were present in patients with myeloproliferative neoplasms (MFN) and essential thrombocythaemia (ET) (4). Calreticulin expression is typically upregulated in most cancer lines, however it is downregulated in some tissues including cervical carcinomas, prostate cancer, and human colon adenocarcinoma (3). High expression of calreticulin on cancer cells is related to tumor cell phagocytosis and is often correlated with, and counteracted by, elevated CD47 expression to prevent cancer cell phagocytosis (3). Calreticulin mutations can serve as a major diagnostic biomarker for MFN and ET and additionally the calreticulin gene may be a potential target for cancer therapeutics (3,4).
References
1. Michalak, M., Groenendyk, J., Szabo, E., Gold, L. I., & Opas, M. (2009). Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. The Biochemical Journal. https://doi.org/10.1042/BJ20081847
2. Fucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021). Calreticulin and cancer. Cell Research. https://doi.org/10.1038/s41422-020-0383-9
3. Sun, J., Mu, H., Dai, K., & Yi, L. (2017). Calreticulin: a potential anti-cancer therapeutic target. Die Pharmazie. https://doi.org/10.1691/ph.2017.7031
4. Prins, D., Gonzalez Arias, C., Klampfl, T., Grinfeld, J., & Green, A. R. (2020). Mutant Calreticulin in the Myeloproliferative Neoplasms. HemaSphere. https://doi.org/10.1097/HS9.0000000000000333
Alternate Names
Autoantigen Ro, CALR, Calregulin, cC1qR, CRT, SSA, Vasostatin
Gene Symbol
CALR
Additional Calreticulin Products
Product Documents for Calreticulin Antibody (6C6) [PerCP]
Product Specific Notices for Calreticulin Antibody (6C6) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...